Key result
Low-dose rosiglitazone and metformin had comparable beneficial impacts on metabolic and hormonal features of PCOS, though rosiglitazone significantly improved endothelial-independent function.
Why the study?
Does low-dose metformin compared to rosiglitazone improve clinical, biochemical, ultrasound features, and endothelial function in women with polycystic ovary syndrome?
RCT (n=35)
Randomized
Does low-dose metformin compared to rosiglitazone improve clinical, biochemical, ultrasound features, and endothelial function in women with polycystic ovary syndrome?
Low-dose metformin and rosiglitazone have comparable beneficial effects on metabolic, hormonal, and morphological features of mild PCOS, but neither significantly improves endothelial-dependent vascular function.
Answers are grounded in this paper and cite their sources.
Comparable metabolic benefits support either agent in mild PCOS; extends evidence on rosiglitazone's selective endothelial-independent effect.
The aim of this study was to compare the effect of low-dose metformin and rosiglitazone on clinical, biochemical, ultrasound features and endothelial function in patients with polycystic ovary syndrome (PCOS). After randomisation, a group of 17 women received metformin 500 mg b.d. (MG) and a group of 18 received rosiglitazone 4 mg o.d. (RG) for 3 months. Serum FSH, LH, testosterone, fasting glucose, insulin, IGF-1, IGFBP-3, CRP were measured at baseline and follow-up. Ovarian scan and microcirculation studies were also performed. It was found that there was a reduction in hyperandrogenaemia, insulin resistance, lipidaemia, CRP levels, ovarian volume and number of follicles in both groups. No improvement in endothelial- dependent function was noted but a significant improvement in endothelial-independent function in rosiglitazone group. It was concluded that low-dose therapeutic regimen with rosiglitazone and metformin, has comparable beneficial impacts on metabolic, hormonal and morphological features of PCOS but no obvious effect on vascular parameters in a population of predominantly mild PCOS.
No takes yet. Share an insight, caveat, or question.
Mohiyiddeen et al. (2013) conducted an RCT in Polycystic ovary syndrome (n=35). Rosiglitazone vs. Metformin (500 mg b.d.) was evaluated on Clinical, biochemical, ultrasound features and endothelial function. Low-dose rosiglitazone and metformin had comparable beneficial impacts on metabolic and hormonal features of PCOS, though rosiglitazone significantly improved endothelial-independent function.
Synapse has enriched 10 related papers. Consider them for comparative context: